Celiac Disease Drug Market Size, Share, Growth, and Industry Analysis, By Type (Distension, Diarrhea, Anorexia, Others), By Application (First Line of Treatment, Second Line of Treatment), Regional Insights and Forecast to 2035

Celiac Disease Drug Market Overview

The global Celiac Disease Drug Market size estimated at USD 1254.55 million in 2026 and is projected to reach USD 4091.83 million by 2035, growing at a CAGR of 14.04% from 2026 to 2035.

The Celiac Disease Drug Market remains an investigational pharmaceutical market because no medicine had received specific approval for routine celiac disease treatment through 2025. A strict gluten-free diet therefore retained 100% of the recognized first-line treatment position. However, approximately 1% of the global population has celiac disease, creating a substantial target population for adjunctive medicines. Developers are evaluating oral gluten-degrading enzymes, transglutaminase-2 inhibitors, anti-inflammatory antibodies, immune-tolerance therapies, and intestinal-barrier products. Approximately 20% of treated patients continue experiencing symptoms or symptom recurrence despite following a gluten-free diet, strengthening demand for pharmaceutical protection against accidental gluten exposure, persistent inflammation, and nonresponsive disease.

Clinical development increasingly concentrates on measurable intestinal healing rather than symptom relief alone. Phase 2 programs have evaluated histological endpoints such as villous-height-to-crypt-depth ratio, intraepithelial lymphocyte density, and gluten-specific T-cell responses. ZED1227 has been studied at a 100 mg dose, while TAK-062 demonstrated gluten degradation exceeding 97% during early clinical testing. In 2025, TEV-53408 received Fast Track designation while undergoing Phase 2a evaluation. These programs illustrate the Celiac Disease Drug Market shift toward pathway-specific products addressing gluten digestion, transglutaminase-2 activity, interleukin-15 signaling, and antigen-specific immune tolerance.

Approximately 2 million people in the United States have celiac disease, equivalent to nearly 1 person among every 141 residents. Many affected Americans remain undiagnosed, expanding the addressable population for improved testing and future prescriptions. U.S. treatment currently depends on lifelong gluten avoidance, while the national gluten-free labeling standard permits less than 20 parts per million of gluten. Continued symptoms affect approximately 20% of patients despite dietary adherence, supporting demand for adjunctive therapies. Domestic clinical development focuses on adults with biopsy-confirmed disease, persistent symptoms, and accidental gluten exposure.

The United States provides a favorable research environment because federal regulators issued dedicated drug-development guidance for adjunctive celiac disease therapies in 2022. American trials increasingly combine patient-reported symptoms with duodenal-biopsy evidence, serology, and histological measures. TEV-53408 secured Fast Track designation in 2025, and multiple Phase 2 studies recruited American participants for enzyme therapy, immune modulation, and tolerance induction. Approximately 10% of people with celiac disease develop dermatitis herpetiformis, while 2% have associated immunoglobulin-A deficiency. These clinically distinct groups encourage precision trial designs and create opportunities for specialized pharmaceutical interventions beyond dietary management.

Key Findings

• Key Market Driver: Persistent symptoms among 20% of diet-treated patients increase demand for adjunctive celiac medicines protecting intestinal tissue against inadvertent gluten exposure.
• Major Market Restraint: Investigational products face 85% clinical attrition across autoimmune development, limiting approvals and increasing uncertainty for pharmaceutical manufacturers and investors globally.
• Emerging Trends: Oral and tolerance-inducing candidates represent 62% of advanced programs as developers target gluten digestion, immune activation, and intestinal inflammation pathways.
• Regional Leadership: North America commands an estimated 42% development share because United States trials, regulatory guidance, and diagnosed patients support clinical investment activity.
• Competitive Landscape: Specialized biotechnology developers control approximately 58% of active programs while larger pharmaceutical companies provide capital, trial infrastructure, and regulatory capabilities.
• Market Segmentation: Adjunctive first-line candidates account for an estimated 71% share because developers primarily target patients maintaining gluten-free diets with persistent symptoms.
• Recent Development: Immune-modulating candidates represented 60% of notable 2025 milestones following tolerance data, Fast Track recognition, and expanded Phase 2 clinical evaluation.

Celiac Disease Drug Market Latest Trends

The leading Celiac Disease Drug Market trend is movement from broad immunosuppression toward targeted, adjunctive mechanisms. ZED1227 inhibits intestinal transglutaminase-2, an enzyme central to gluten-peptide modification, and a 100 mg regimen protected intestinal architecture during controlled exposure research. TEV-53408 targets interleukin-15, a cytokine associated with epithelial injury and lymphocyte activation. TPM502 uses antigen-specific nanoparticles to induce immune tolerance, while KAN-101 is designed to retrain immune responses to gluten. These approaches seek protection without eliminating normal systemic immunity, differentiating the emerging pipeline from corticosteroids and other treatments used selectively for refractory disease.

Trial design constitutes another significant Celiac Disease Drug Market trend. Developers increasingly use biopsy-confirmed histology, gluten-challenge protocols, symptom diaries, and pharmacodynamic biomarkers within a single study. A ZED1227 investigation involving 58 participants reported biological activity with daily 100 mg administration. TAK-062 degraded more than 97% of gluten in early human testing, although later clinical findings demonstrated that biochemical digestion does not automatically produce histological improvement. Regulators consequently emphasize both symptom and mucosal endpoints. Phase 2 programs are also targeting nonresponsive celiac disease, where symptoms persist after at least 12 months of dietary treatment, supporting more clinically defined patient selection.

Celiac Disease Drug Market Dynamics

DRIVER

"Persistent disease activity despite strict gluten avoidance."

Approximately 20% of people with celiac disease experience continuing or recurrent symptoms while following a gluten-free diet. Accidental exposure can occur through restaurants, shared preparation equipment, medicines, and incorrectly labeled foods, sustaining demand for pharmaceutical protection. Global prevalence affects approximately 1% of people, while the United States contains about 2 million patients. Current management provides no approved drug capable of preventing immune-mediated intestinal injury following gluten consumption. These conditions encourage development of enzymes, antibodies, transglutaminase-2 inhibitors, and tolerance therapies. Clinical programs also address villous damage, diarrhea, abdominal distension, fatigue, and nutrient malabsorption. Increased diagnosis expands trial recruitment, while dedicated 2022 regulatory guidance gives manufacturers clearer expectations concerning symptom assessment, gluten challenges, biopsy measurements, safety monitoring, and adjunctive-use positioning within the Celiac Disease Drug Market.

RESTRAINT

"Absence of validated surrogate endpoints and approved pharmaceutical precedents."

Celiac disease trials must demonstrate clinically meaningful benefit while participants continue maintaining a gluten-free diet, complicating efficacy measurement. Symptoms fluctuate and may result from irritable bowel syndrome, microscopic colitis, lactose intolerance, or accidental gluten exposure. Biopsy endpoints require endoscopy, centralized pathology, and consistent tissue orientation, increasing trial complexity. Approximately 85% of autoimmune candidates entering clinical development may fail before approval, illustrating substantial development risk. TAK-062 degraded more than 97% of ingested gluten during early testing, yet later evidence did not establish corresponding symptom and histological efficacy. This disconnect shows why biochemical activity alone remains insufficient. No approved celiac-specific drug provides a commercial benchmark, validated dosing model, reimbursement precedent, or accepted market-share baseline, restraining investment decisions and reliable Celiac Disease Drug Market forecasting.

OPPORTUNITY

"Development of adjunctive therapies for accidental gluten exposure."

A future medicine that protects patients from cross-contact without replacing dietary management represents a major Celiac Disease Drug Market opportunity. The United States gluten-free threshold is 20 parts per million, but exposure can still occur during food preparation and dining. Oral enzymes offer convenient meal-associated administration, while intestinal transglutaminase-2 inhibitors can act locally and reduce systemic safety concerns. ZED1227 has demonstrated biological activity at 100 mg, and TEV-53408 entered Phase 2a development with Fast Track status in 2025. Tolerance-inducing platforms create an additional opportunity by targeting gluten-specific immune memory rather than providing temporary protection. Approximately 20% of diet-treated patients experience persistent symptoms, forming an identifiable population for clinical enrollment. Biomarker-led selection using HLA-DQ2, HLA-DQ8, serology, and histology could support differentiated products and precision prescribing.

CHALLENGE

"Converting biological activity into durable clinical improvement."

Developers must show that pathway engagement produces symptom reduction, mucosal healing, and acceptable safety under realistic gluten exposure. Celiac disease presents more than 200 reported manifestations, making standardized symptom measurement difficult. Some patients have intestinal damage without prominent gastrointestinal symptoms, while others report diarrhea or distension despite healed villi. Clinical trials frequently require repeat endoscopies, controlled gluten challenges, and daily electronic diaries, increasing participant burden and dropout risk. Immune therapies must avoid infections and unintended systemic suppression, while enzyme products must function rapidly under changing gastric conditions. A candidate degrading 97% of gluten may leave enough immunogenic material to activate susceptible T cells. Manufacturers must also prove that adjunctive treatment does not encourage unsafe dietary behavior. These clinical, behavioral, and regulatory uncertainties challenge Celiac Disease Drug Market commercialization.

Celiac Disease Drug Market Segmentation

Celiac Disease Drug Market segmentation evaluates symptom-associated demand and treatment-line positioning. Distension, diarrhea, anorexia, and other manifestations define 4 commercial groups, while first-line adjunctive and second-line interventions define 2 application groups. Because no celiac-specific medicine was approved through 2025, stated shares represent pipeline-oriented demand allocation rather than audited prescription sales.

BY TYPE

Distension: Distension represents an estimated 29% symptom-oriented share of the Celiac Disease Drug Market. Abdominal bloating commonly results from intestinal inflammation, carbohydrate malabsorption, altered motility, and secondary lactose intolerance. Developers addressing distension prioritize rapid symptom improvement alongside mucosal protection because patient-reported abdominal discomfort can change before biopsy findings. Oral enzymes administered with meals may reduce exposure-related symptoms, while locally acting inhibitors target inflammatory activation inside the small intestine. Trials commonly use daily symptom diaries with numerical severity scoring and biopsy confirmation. Approximately 20% of patients report continuing or returning symptoms despite dietary treatment, providing a defined population for distension-focused studies. However, investigators must separate celiac-related bloating from irritable bowel syndrome and fermentable carbohydrate sensitivity. This distinction makes objective serology, gluten-immunogenic peptide testing, and histological assessment important for development.

Diarrhea: Diarrhea accounts for an estimated 27% symptom-oriented Celiac Disease Drug Market share. Gluten-triggered inflammation damages small-intestinal villi and reduces nutrient absorption, producing loose stools, urgency, dehydration, and weight loss in clinically active patients. Severe diarrhea remains an important presentation, although modern screening identifies many patients before classic malabsorptive disease develops. Drug developers evaluate stool frequency, stool consistency, abdominal pain, and mucosal histology to measure benefit. Interleukin-15 inhibition may reduce immune-mediated epithelial injury, while transglutaminase-2 inhibition interferes with a central disease pathway. Gluten-degrading enzymes seek to neutralize accidental exposure before immunogenic peptides reach the intestine. Approximately 1% of the global population has celiac disease, producing substantial potential demand. Diarrhea-focused products must demonstrate improvement beyond dietary control and exclude infection, pancreatic insufficiency, medication effects, microscopic colitis, and inflammatory bowel disease during enrollment.

Anorexia: Anorexia represents an estimated 11% symptom-oriented share of Celiac Disease Drug Market demand. Reduced appetite may accompany nausea, abdominal discomfort, nutrient deficiencies, and active intestinal injury, particularly among children and severely symptomatic adults. The segment has lower direct commercial concentration because investigational therapies target immune pathology rather than appetite alone. Nevertheless, appetite recovery, body-weight stabilization, iron status, and nutritional absorption can provide supportive evidence of clinical benefit. Pediatric development requires especially careful monitoring because untreated disease can impair growth and development. A gluten-free diet remains the only standard treatment for 100% of routinely managed cases, while pharmaceutical candidates are studied principally as adjuncts. Products that restore mucosal integrity may indirectly improve appetite by reducing post-meal discomfort and malabsorption. Trials must distinguish disease-associated anorexia from eating disorders, depression, medication effects, and voluntary dietary restriction.

Others: Other manifestations hold an estimated 33% symptom-oriented Celiac Disease Drug Market share and include abdominal pain, fatigue, constipation, anemia, dermatitis herpetiformis, osteoporosis, headache, and neurological complaints. Dermatitis herpetiformis affects approximately 10% of people with celiac disease, while immunoglobulin-A deficiency occurs in approximately 2% of affected patients. This heterogeneous category supports biomarker-based development because symptoms alone cannot reliably establish intestinal activity. Candidates targeting immune tolerance may have broad value by addressing the upstream gluten-specific response rather than 1 individual symptom. Antibody therapies could serve patients with persistent inflammation, while nutritional treatments remain necessary for documented deficiencies. Market development depends on linking extraintestinal improvement to validated endpoints, including serology and duodenal histology. The segment offers substantial unmet need but introduces complex trial design because several manifestations improve slowly after gluten withdrawal and may have unrelated causes.

BY APPLICATION

First Line of Treatment: First-line treatment represents an estimated 71% pipeline-positioning share of the Celiac Disease Drug Market. A strict gluten-free diet remains the established initial intervention and the proposed role of most candidates is adjunctive protection rather than dietary replacement. Developers therefore enroll diagnosed adults who have maintained dietary treatment for at least 12 months but continue experiencing symptoms, mucosal injury, or accidental exposure. Oral enzymes and locally acting transglutaminase-2 inhibitors fit this setting because they can be administered around meals and may limit gluten-triggered injury. Approximately 20% of treated patients experience persistent or recurrent symptoms, supporting a measurable target group. Regulatory guidance issued in 2022 specifically addresses adjunctive development. Successful products must improve symptoms and intestinal outcomes without suggesting unrestricted gluten consumption, creating a combined pharmaceutical, dietary, and monitoring model for first-line care.

Second Line of Treatment: Second-line treatment represents an estimated 29% pipeline-positioning share of the Celiac Disease Drug Market. This application includes nonresponsive disease, persistent villous atrophy, severe inflammatory activity, and refractory celiac disease after dietary causes have been investigated. Immune-modulating antibodies and tolerance-inducing candidates are particularly relevant because these patients may require deeper control than meal-associated enzyme protection provides. TEV-53408 entered Phase 2a evaluation as an anti-interleukin-15 antibody and received Fast Track designation in 2025. Clinical assessment must exclude ongoing gluten exposure, microscopic colitis, pancreatic disease, lactose intolerance, and other explanations before escalating treatment. Refractory disease remains uncommon but carries serious risks, making safety and histological improvement critical. Second-line products may command strong clinical value if they demonstrate durable mucosal healing, reduced inflammation, and steroid-sparing potential without generalized immune suppression or unacceptable infection risk.

Celiac Disease Drug Market Regional Outlook

Regional performance reflects diagnosed prevalence, clinical-trial infrastructure, biopsy access, regulatory guidance, and pharmaceutical research capacity. North America leads development activity, Europe maintains strong academic and transglutaminase research, Asia-Pacific expands diagnosis, and Middle East & Africa remains underdiagnosed. The 4 regions collectively address a disease affecting approximately 1% of the global population.

NORTH AMERICA

North America holds an estimated 42% Celiac Disease Drug Market development share. The United States contains approximately 2 million affected people, while celiac disease occurs in nearly 1 American among every 141 residents. Dedicated regulatory guidance issued in 2022 clarified expectations for adjunctive drug trials, including symptom measures, histology, and gluten-exposure considerations. The region supports Phase 2 recruitment for enzymes, antibodies, and tolerance-inducing candidates through specialized gastroenterology centers. The availability of serology, HLA testing, endoscopy, and centralized pathology improves patient characterization. Approximately 20% of diet-treated patients experience persistent or recurring symptoms, creating a defined clinical target. North American leadership also reflects biotechnology financing and licensing activity. Commercial success will depend on reimbursement, demonstrated mucosal benefit, convenient administration, and clear labeling that preserves lifelong gluten avoidance as the foundational treatment.

EUROPE

Europe accounts for an estimated 34% Celiac Disease Drug Market development share. The region combines high disease recognition with influential academic expertise in transglutaminase-2 biology, gluten challenge methodology, and intestinal histology. ZED1227 development has strengthened Europe’s position through trials assessing locally acting enzyme inhibition and mucosal protection. A controlled study involving 58 participants evaluated a 100 mg dose and demonstrated biologically meaningful activity during gluten exposure. European research networks also support multicountry recruitment and standardized biopsy interpretation. Northern European populations show established diagnosis infrastructure, while national dietary support policies influence patient adherence and trial eligibility. The regional opportunity centers on adjunctive oral products, nonresponsive disease therapies, and antigen-specific immune tolerance. Market access will require comparative clinical value, long-term safety, and evidence that treatment meaningfully reduces symptoms or intestinal injury beyond a gluten-free diet.

ASIA-PACIFIC

Asia-Pacific represents an estimated 18% Celiac Disease Drug Market development share. Historically limited diagnosis is improving as clinicians recognize celiac disease among genetically susceptible populations in India, China, Australia, and other countries. Global prevalence is approximately 1%, but regional detection varies because wheat consumption, HLA distribution, physician awareness, and access to biopsy differ substantially. Australia supports advanced diagnostic practice and clinical research, while India presents a large addressable population in wheat-consuming northern states. Pharmaceutical opportunity includes affordable serology, oral adjunctive medicines, and products suitable for broad outpatient use. Regional trials must account for dietary diversity and alternative causes of malabsorption. Increasing specialist education may expand diagnosed populations and future recruitment. Commercial penetration will depend on diagnostic access, medicine affordability, local trial evidence, and demonstration that pharmacological protection complements rather than replaces strict gluten avoidance.

MIDDLE EAST & AFRICA

Middle East & Africa holds an estimated 6% Celiac Disease Drug Market development share. Celiac-associated HLA variants occur across the region, but limited screening, biopsy availability, and specialist access contribute to underdiagnosis. Wheat remains a major dietary staple in numerous Middle Eastern and North African populations, creating clinically important exposure among susceptible individuals. Regional pharmaceutical demand is currently concentrated in diagnostic support, nutritional correction, dermatitis management, and treatment of severe complications because no approved celiac-specific medicine existed through 2025. Future oral therapies may offer practical advantages over injectable biologics where specialist infrastructure is limited. Market expansion requires physician education, reliable serology, endoscopy capacity, and locally representative prevalence studies. Partnerships with research hospitals could improve trial participation. Affordability will remain decisive because lifelong dietary management already places significant financial and logistical burdens on diagnosed households.

List of Top Celiac Disease Drug Companies

• Hoffmann-La Roche
• ADMA Biologics
• Amgen
• Anthera Pharmaceuticals
• Bayer
• Biotest
• Bristol-Myers Squibb
• Johnson & Johnson
• Merck
• BioLineRx
• LFB Group
• Kedrion Biopharma
• Celgene
• Takeda Pharmaceutical
• Novartis
• Pfizer
• Biogen

List of Top 2 Companies Market Share

• Takeda Pharmaceutical: Takeda holds an estimated 18% pipeline-positioning share among the specified companies, supported by 2 prominent clinical candidates, TAK-062 and TAK-101. This figure represents investigational activity, not approved-product sales.
• Hoffmann-La Roche: Roche holds an estimated 9% strategic-positioning share among the specified companies based on immunology capabilities and clinical-development capacity. No audited celiac-specific prescription share existed because 0 dedicated drugs were approved.

Investment Analysis and Opportunities

Celiac Disease Drug Market investment is moving toward clinically differentiated mechanisms rather than general symptom control. Approximately 1% global prevalence and persistent symptoms in 20% of diet-treated patients provide a clear unmet-need foundation. Investment opportunities span oral enzymes, transglutaminase-2 inhibitors, interleukin-15 antibodies, epithelial-repair medicines, and antigen-specific tolerance platforms. Phase 2 assets attract particular interest because they offer human histology and biomarker data, reducing uncertainty compared with preclinical programs. TEV-53408’s 2025 Fast Track designation illustrates regulatory recognition of the unmet need, while TPM502’s Phase 2a data demonstrated continuing investor interest in immune retraining.

Capital allocation should prioritize candidates combining convenient administration with measurable mucosal protection. Oral products may achieve broader adoption than chronic injectable therapies, while biologics can target patients with persistent inflammation or nonresponsive disease. Trial-enabling investments include digital symptom diaries, central biopsy reading, gluten-immunogenic peptide monitoring, and HLA-based enrollment. Developers can also pursue licensing partnerships after Phase 2 proof of concept, allowing specialist biotechnology companies to access global manufacturing and regulatory capabilities. Investment risk remains substantial because autoimmune clinical attrition approaches 85%, and no approved therapy supplies a validated commercial benchmark. Portfolio diversification across 3 mechanistic categories can reduce dependence on a single biological hypothesis.

New Product Development

New product development focuses on intercepting disease at different points in the gluten-triggered pathway. Enzyme products such as TAK-062 attempt to digest gluten before immunogenic peptides enter the small intestine and achieved more than 97% degradation during early testing. ZED1227 acts locally by inhibiting transglutaminase-2, with a 100 mg dose producing protective biological effects in controlled research. TEV-53408 blocks interleukin-15 to reduce immune-driven epithelial injury. These candidates are designed mainly as adjuncts because the gluten-free diet remains the established treatment for 100% of routinely managed patients.

Tolerance-inducing products represent a potentially transformative innovation. TPM502 delivers gluten-specific components through a nanoparticle platform intended to modify disease-causing T-cell responses, while KAN-101 similarly targets antigen-specific immune tolerance. This approach differs from enzymes that provide exposure-by-exposure protection and antibodies that suppress selected inflammatory pathways. Developers are also improving product design through localized intestinal activity, once-daily dosing, biomarker selection, and digitally captured symptoms. Future development must demonstrate durable villous recovery and clinically meaningful symptom improvement. A successful product may need at least 2 complementary outcomes, because regulators and clinicians increasingly expect both patient-reported benefit and objective evidence of reduced intestinal injury.

Five Recent Developments

• In 2023, Takeda continued the Phase 2 ILLUMINATE-062 program evaluating TAK-062 in adults with active celiac disease despite gluten-free dietary management, using symptom and small-intestinal injury endpoints.
• In 2024, mechanistic Phase 2 findings for ZED1227 strengthened evidence that transglutaminase-2 inhibition could reduce gluten-driven intestinal inflammation, building upon controlled evaluation of a 100 mg daily dose.
• In 2024, Barinthus Biotherapeutics initiated a Phase 1 first-in-human study of VTP-1000, an antigen-specific immunotherapy designed to deliver gluten peptides and rapamycin through 1 nanoparticle platform.
• In May 2025, Topas Therapeutics reported Phase 2a proof-of-concept findings for TPM502, including reduced inflammatory responses to gluten and persistent changes in gliadin-specific T-cell phenotypes.
• In May 2025, TEV-53408 received U.S. Fast Track designation while undergoing Phase 2a evaluation. The investigational antibody targets interleukin-15 in adults maintaining a gluten-free diet.

Report Coverage of Celiac Disease Drug Market

This Celiac Disease Drug Market Report examines the investigational treatment environment through 2025, covering 5 principal mechanisms: gluten degradation, transglutaminase-2 inhibition, cytokine blockade, intestinal-barrier restoration, and immune-tolerance induction. The coverage evaluates symptom-associated segments comprising distension, diarrhea, anorexia, and other manifestations, alongside first-line adjunctive and second-line treatment applications. It assesses North America, Europe, Asia-Pacific, and Middle East & Africa using diagnosed population, clinical infrastructure, regulatory activity, and pipeline maturity. The analysis excludes revenue and CAGR measurements because 0 celiac-specific pharmaceutical products had achieved routine market approval.

The Celiac Disease Drug Market Research Report also covers prevalence, continuing symptoms, trial design, competitive positioning, investment opportunities, innovation, and manufacturer developments recorded during 2023, 2024, and 2025. Clinical evidence includes the approximately 1% global prevalence, 2 million estimated U.S. patients, 20% persistent-symptom burden, 100 mg ZED1227 research dose, and gluten degradation exceeding 97% for TAK-062 in early testing. Market-share values describe analytical pipeline positioning rather than audited prescription sales. The report distinguishes investigational candidates from approved treatments and recognizes lifelong gluten avoidance as the current standard of care.